Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $804.3KOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Flynn James P | Director | Jun 24 '26 | Buy | $0.86 | 25,000 | $21,388 | 125,000 | Jun 25 04:30 PM |
| Schornstein Alexander | 10% Owner | Dec 18 '25 | Sale | $1.37 | 690,611 | $946,137 | 3,674,862 | Dec 22 04:15 PM |
Company profile
MEI Pharma is a biotechnology company in the healthcare sector.
Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Flynn James P | Director | Dec 19 '25 | Buy | $1.40 | 70,000 | $97,699 | 100,000 | Dec 22 04:00 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.